Failed 5mg results not bad for Acorda's Ampyra; but 'meh' 10mg could hurt
This article was originally published in Scrip
Executive Summary
Normally, a failed clinical trial would not be good news for a drug maker. But for Acorda Therapeutics, the failure of the firm's study to show efficacy with the 5mg dose of its multiple sclerosis (MS) drug Ampyra (dalfampridine) was somewhat welcomed news for investors.